title: Dexamethasone for the prevention of nausea and vomiting after dilatation and curettage: a randomized controlled trial.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of dexamethasone administered intravenously at three different doses (4 mg, 8 mg, 16 mg) for the prevention of nausea and vomiting after dilatation and curettage.
  
  
  METHODS
  In a prospective, randomized, double-masked, placebo-controlled trial, 120 women received placebo or dexamethasone intravenously at doses of 4 mg, 8 mg, or 16 mg immediately before induction of anesthesia (n = 30 in each group). Propofol-based general anesthetic was used. Emetic episodes and safety assessments were performed. To estimate a sufficient sample size, it was calculated that 30 patients per group would be required with alpha =.05 and beta =.2.
  
  
  RESULTS
  The rate of patients who were emesis-free (no nausea, retching, or vomiting) 0-24 hours after anesthesia was 57% with dexamethasone 4 mg (P =.796), 87% with dexamethasone 8 mg (P =.005), and 87% with dexamethasone 16 mg (P =.005), compared with placebo (50%). Patients who had received dexamethasone 8 mg or 16 mg were more satisfied than those who had received placebo (P <.05). No clinically important adverse events were observed in any of the groups.
  
  
  CONCLUSIONS
  Dexamethasone 8 mg is an effective antiemetic for preventing postoperative nausea and vomiting 0-24 hours after anesthesia in women undergoing propofol-based general anesthesia for termination of pregnancy. Increasing the dose to 16 mg provided no additional benefit.
authors.affiliation: Department of Anesthesiology, University of Tsukuba Institute of Clinical Medicine, Tsukuba City, Ibaraki, Japan. jfujii@igaku.tsukuba.ac.jp
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Fujii
authors.forename: Aki
authors.initials: A
authors.lastname: Uemura
mesh_terms: D000328:Adult; D000768:Anesthesia, General / Q000009:adverse effects* / Q000379:methods; D003907:Dexamethasone / Q000008:administration & dosage*; D004107:Dilatation and Curettage / Q000009:adverse effects / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017060:Patient Satisfaction; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*; D011247:Pregnancy; D011336:Probability; D011446:Prospective Studies; D012016:Reference Values; D016896:Treatment Outcome
chemical_list: D003907:Dexamethasone